Skip to main content
IBRX
NASDAQ Life Sciences

ImmunityBio的Q1收入飙升168%至创纪录的4400万美元，现金接近3.81亿美元

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
8
Price
$6.94
Mkt Cap
$7.176B
52W Low
$1.83
52W High
$12.43
Market data snapshot near publication time

summarizeSummary

ImmunityBio宣布强劲的初步Q1 2026年财务结果，报告创纪录的4400万美元的净产品收入，代表着同比大幅增加168%。这一表现继续保持ANGTIVA的正向商业轨迹，继公司最近2025年年度报告中强调的700%收入增长之后。该公司还报告称，截至季度末，现金和可市场证券余额约为3.81亿美元。这一显著的收入增长和坚实的现金状况具有高度的重要性，表明了强劲的商业执行和财务稳定。投资者将监测即将发布的完整Q1 10-Q，以获取详细的财务数据和ANGTIVA的市场渗透和产品线进展的进一步更新，包括计划提交的补充BLA。

在该公告发布时，IBRX的交易价格为$6.94，交易所为NASDAQ，所属行业为Life Sciences，市值约为$71.8亿。 52周交易区间为$1.83至$12.43。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed IBRX - Latest Insights

IBRX
Apr 29, 2026, 7:48 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Proxy Statement Details Shareholder Meeting, Executive Pay, and Significant Related-Party Convertible Debt
Sentiment: Negative
View Wiseek Article
IBRX
Apr 09, 2026, 7:39 AM EDT
Filing Type: 8-K
Importance Score:
8
ImmunityBio Reports Record Q1 Revenue and Strong Cash Position, Driven by ANKTIVA Growth
Sentiment: Positive
View Wiseek Article
IBRX
Apr 09, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
ImmunityBio's Q1 Revenue Jumps 168% to Record $44M, Cash Nears $381M
Sentiment: Positive
View Wiseek Article
IBRX
Apr 06, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
7
ImmunityBio Responds to FDA Warning Letter, Clarifies Ad Never Aired
Sentiment: Neutral
View Wiseek Article
IBRX
Mar 31, 2026, 8:24 AM EDT
Filing Type: 8-K
Importance Score:
9
ImmunityBio Secures $100M Financing, Including $75M Non-Dilutive Capital, Amidst Global ANKTIVA Approvals
Sentiment: Positive
View Wiseek Article
IBRX
Mar 31, 2026, 7:39 AM EDT
Source: Reuters
Importance Score:
7
ImmunityBio Secures $100M Financing, $75M Non-Dilutive, to Fuel Global Expansion and Pipeline
Sentiment: Positive
View Wiseek Article
IBRX
Mar 24, 2026, 11:33 AM EDT
Source: Reuters
Importance Score:
8
FDA Issues Warning to ImmunityBio Over 'False or Misleading' Anktiva Cancer Claims
Sentiment: Negative
View Wiseek Article
IBRX
Feb 23, 2026, 5:24 PM EST
Filing Type: 10-K
Importance Score:
8
ImmunityBio Reports 700% ANKTIVA Revenue Growth and Expanded Global Approvals in 2025 Annual Report
Sentiment: Neutral
View Wiseek Article
IBRX
Feb 23, 2026, 7:06 AM EST
Filing Type: 8-K
Importance Score:
8
ImmunityBio Reports 700% Revenue Growth, Global ANKTIVA Approvals, and First Lung Cancer Indication
Sentiment: Positive
View Wiseek Article
IBRX
Feb 18, 2026, 9:02 AM EST
Filing Type: 8-K
Importance Score:
9
ImmunityBio's ANKTIVA Receives EU Authorization for Bladder Cancer, Expanding Global Access
Sentiment: Positive
View Wiseek Article